Xiao Kunmin, Li Kexin, Long Sidan, Kong Chenfan, Zhu Shijie
Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China.
Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China.
Evid Based Complement Alternat Med. 2020 Sep 25;2020:3670309. doi: 10.1155/2020/3670309. eCollection 2020.
Breast cancer is one of the most common cancers endangering women's health all over the world. Traditional Chinese medicine is increasingly recognized as a possible complementary and alternative therapy for breast cancer. Chaihu-Shugan-San is a traditional Chinese medicine prescription, which is extensively used in clinical practice. Its therapeutic effect on breast cancer has attracted extensive attention, but its mechanism of action is still unclear. In this study, we explored the molecular mechanism of Chaihu-Shugan-San in the treatment of breast cancer by network pharmacology. The results showed that 157 active ingredients and 8074 potential drug targets were obtained in the TCMSP database according to the screening conditions. 2384 disease targets were collected in the TTD, OMIM, DrugBank, GeneCards disease database. We applied the Bisogenet plug-in in Cytoscape 3.7.1 to obtain 451 core targets. The biological process of gene ontology (GO) involves the mRNA catabolic process, RNA catabolic process, telomere organization, nucleobase-containing compound catabolic process, heterocycle catabolic process, and so on. In cellular component, cytosolic part, focal adhesion, cell-substrate adherens junction, and cell-substrate junction are highly correlated with breast cancer. In the molecular function category, most proteins were addressed to ubiquitin-like protein ligase binding, protein domain specific binding, and Nop56p-associated pre-rRNA complex. Besides, the results of the KEGG pathway analysis showed that the pathways mainly involved in apoptosis, cell cycle, transcriptional dysregulation, endocrine resistance, and viral infection. In conclusion, the treatment of breast cancer by Chaihu-Shugan-San is the result of multicomponent, multitarget, and multipathway interaction. This study provides a certain theoretical basis for the treatment of breast cancer by Chaihu-Shugan-San and has certain reference value for the development and application of new drugs.
乳腺癌是全球危害女性健康的最常见癌症之一。中医日益被认为是乳腺癌一种可能的补充和替代疗法。柴胡疏肝散是一种中药方剂，在临床实践中被广泛应用。其对乳腺癌的治疗作用已引起广泛关注，但其作用机制仍不清楚。在本研究中，我们通过网络药理学探讨了柴胡疏肝散治疗乳腺癌的分子机制。结果显示，根据筛选条件在中药系统药理学数据库（TCMSP）中获得了157种活性成分和8074个潜在药物靶点。在治疗靶点数据库（TTD）、在线人类孟德尔遗传数据库（OMIM）、药物银行（DrugBank）、基因卡片疾病数据库中收集了2384个疾病靶点。我们在Cytoscape 3.7.1中应用双基因网络（Bisogenet）插件获得了451个核心靶点。基因本体（GO）的生物学过程涉及mRNA分解代谢过程、RNA分解代谢过程、端粒组织、含核碱基化合物分解代谢过程、杂环分解代谢过程等。在细胞组成部分中，胞质部分、粘着斑、细胞-底物粘附连接和细胞-底物连接与乳腺癌高度相关。在分子功能类别中，大多数蛋白质涉及泛素样蛋白连接酶结合、蛋白质结构域特异性结合和与Nop56p相关的前体rRNA复合物。此外，京都基因与基因组百科全书（KEGG）通路分析结果表明，这些通路主要涉及细胞凋亡、细胞周期、转录失调、内分泌抵抗和病毒感染。总之，柴胡疏肝散治疗乳腺癌是多成分、多靶点、多途径相互作用的结果。本研究为柴胡疏肝散治疗乳腺癌提供了一定的理论依据，对新药的开发应用具有一定的参考价值。
